Tandem’s t:slim X2 insulin pump now works with Abbott’s FreeStyle Libre 3 Plus CGM, bringing real-time glucose data every minute to its Control-IQ+ system. This marks Libre 3 Plus’ fourth integration into a U.S.-based automated insulin delivery (AID) system—and it likely won’t be the last. Tandem also announced plans to integrate Abbott’s upcoming glucose-ketone sensor, a promising advancement for those at risk of diabetic ketoacidosis (DKA).

The Libre 3 Plus brings continuous glucose readings to the pump every minute, offering a 15-day wear time and a 60-minute warm-up. Data can be viewed on both the pump and the Tandem mobile app, giving users greater flexibility and real-time insight into their trends. With this integration, Abbott is quickly becoming a serious competitor to Dexcom, which is currently facing backlash over widespread G7 sensor failures, shortages, and growing concerns about transparency.

With this latest announcement, Abbott’s Libre 3 Plus is now supported by four AID systems in the U.S.: the Tandem t:slim X2, mylife Loop, twiist, and the iLet Bionic Pancreas. As more pump manufacturers bring the Libre 3 Plus into their ecosystems, Abbott’s sensor platform is clearly catching up in both capability and reach.

The t:slim X2 is powered by Tandem’s Control-IQ+ algorithm, which adjusts insulin every 5 minutes based on predicted glucose values. It’s the only FDA cleared system that allows users to set a Temp Basal while in automated insulin delivery mode. Alongside this new CGM integration, Tandem is also preparing to launch a new 7-day infusion set—designed to reduce site changes and improve comfort for users.

Looking ahead, it’s likely we’ll see Libre 3 Plus support on Tandem Mobi, Tandem’s smaller tubed pump, though no official timeline has been confirmed. For now, an early access program for the t:slim X2 integration has begun in the U.S., with wider rollout expected in the second half of 2025.